Telomir Pharmaceuticals, Inc.

**Telomir Pharmaceuticals** is a biotechnology startup based in the **United States** that was founded in **2022**. The company's mission revolves around the development of a groundbreaking small molecule aimed at regulating telomere length and genomic stability. This innovative treatment involves the selective binding of critical metals to interrupt enzyme function, thereby restoring cellular metal levels such as iron, copper, and zinc to normal and effectively halting the underlying mechanisms driving cancer development and growth. Telomir Pharmaceuticals' flagship product, Telomir 1, stands out for its ability to target specific classes of enzymes through its metal-binding properties, which is anticipated to selectively influence the processes driving iron and copper concentration and accumulation in the serum. This unique approach positions Telomir 1 as a potential game-changer in addressing diseases such as hemochromatosis and cancer. Currently, there is no public information available regarding the company's last investment or the involved investors. The company's innovative approach and focus on addressing critical medical needs in the biotechnology, healthcare, and pharmaceutical sectors make Telomir Pharmaceuticals a compelling prospect for potential **venture capital** investment. The unique mechanism of action and the potential to disrupt the existing treatment landscape for diseases like cancer and hemochromatosis position Telomir Pharmaceuticals as a noteworthy contender in the biotechnology space. As the company continues to advance its novel treatments, it presents an intriguing opportunity for investors seeking to support pioneering solutions in the healthcare and pharmaceutical industries.